What's Happening?
Arima Genomics, a cancer diagnostics company, has announced new findings that demonstrate the effectiveness of Hi-C sequencing in identifying clinically relevant lymphoma rearrangements. These findings will be presented at the Association for Molecular
Pathology (AMP) 2026 Europe Congress. The Hi-C sequencing approach, available through Arima's Aventa Lymphoma test, has shown to detect rearrangements involving key lymphoma-associated genes such as MYC, BCL2, BCL6, CCND1, and IRF4, which are often missed by high-coverage whole genome sequencing (WGS). In a comparative study, Hi-C sequencing identified 37 clinically relevant structural variants in 25 FFPE lymphoma specimens, outperforming WGS, which detected only a fraction of these rearrangements. The study highlights the limitations of WGS, particularly in detecting immunoglobulin-associated rearrangements, and underscores the potential of Hi-C sequencing in providing a comprehensive view of genome structure for accurate lymphoma diagnosis.
Why It's Important?
The findings from Arima Genomics are significant as they highlight a potential shift in the approach to lymphoma diagnosis and classification. Hi-C sequencing's ability to detect a broader range of clinically relevant rearrangements could lead to more accurate and comprehensive diagnostic processes. This advancement is crucial for the medical community as it addresses the limitations of current methods like WGS and FISH, which may miss critical genetic alterations. By improving the detection of these rearrangements, Hi-C sequencing could enhance the precision of lymphoma treatment plans, potentially leading to better patient outcomes. The adoption of this technology could also influence the broader field of cancer diagnostics, encouraging further research and development in genome sequencing technologies.
What's Next?
Arima Genomics plans to present additional data at the AMP 2026 Europe Congress, further supporting the use of Hi-C sequencing as a superior method for detecting diagnostic, prognostic, and therapeutic biomarkers in lymphoma. The company aims to establish Hi-C sequencing as a standard approach in routine lymphoma biopsies, potentially influencing clinical guidelines and practices. As the medical community evaluates these findings, there may be increased interest in integrating Hi-C sequencing into clinical workflows, which could lead to collaborations with healthcare providers and research institutions. The broader acceptance of this technology could also prompt regulatory discussions regarding its implementation in clinical settings.
